Phaseline

Companies › Kunming Pharmaceuticals

Kunming Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KPCXM18 injection–Phase 2Acute Ischemic Stroke–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07279493KPCXM18 injectionPhase 2Acute Ischemic StrokeNeurologyOct 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.